NTRA
Signatera MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
Article Summary
HOLD- Natera Inc. (NASDAQ: NTRA) announced publication of results from prospective multicenter study in Merkel cell carcinoma published in JAMA Dermatology showing Signatera MRD test significantly stronger predictor of recurrence than Merkel cell polyomavirus antibody test (AMERK) across sensitivity, positive and negative predictive value, and lead time to recurrence.
- The global leader in cell-free DNA and precision medicine outperformed AMERK across every key measure in this study including sensitivity, hazard ratios, predictive values and lead-time to detection.
- The study evaluated the SignaterA test against the Merkel cellpolyomav virus antibody test in 169 patients with MCC with AMERK having been the best available tool for years but its inability to function in virus-negative patients and after immunotherapy having been recognized limitation.
- Natera's clinical validation has been published across all MCC patients irrespective of viral status leading to inclusion in NCCN Guidelines as recommendation for surveillance monitoring.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 36.6% | 25% | 85.0 ptsExcellent (36.6%) - Strong growth |
| EPS Growth Next 5Y ? | 0.0% | 25% | 10.0 ptsVery Weak (0.0%) - Minimal expectations |
| Target Price Upside ? | 8.4% | 20% | 35.0 ptsBelow Screener (8.4%) - Target: $283.81 vs Current: $261.88 |
| Gross Margin % ? | 64.8% | 15% | 80.0 ptsVery Healthy (64.8%) - High-quality margins |
| Drawdown from 52-Wk High ? | -9.1% | 15% | 20.0 ptsBarely a Dip (-9.1%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About NTRA
- Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
- It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
- The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions.
- In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model.
- Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services.
- The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model.
- It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use.
- The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma.
- The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012.
- Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.